[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ascvd-management\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ascvd-management":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,73,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100569205","phase-2-effects-of-il-1-beta-inhibition-on-vascular-inflammation-in-tet2-clonal-hematopoiesis-100569205",false,"NCT06691217","Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis","TECTONIC","Inclusion Criteria:\n\n* 18 years or older\n* Coronary artery disease, defined as prior heart attack, coronary stent procedure \\>180 days before baseline imaging, or advanced subclinical coronary atherosclerosis (coronary artery calcium score ≥300 Agatston units, CAD-RADS 3 or greater atherosclerosis on coronary CT angiography, or qualitatively severe coronary artery calcification identified on non-gated CT imaging)\n* Presence of either TET2 mutations or no myeloid driver mutations on prior sequencing\n\nExclusion Criteria:\n\n* placement of a drug-eluting stent in a proximal coronary arterial segment \\\u003C180 days before baseline imaging\n* prior coronary artery bypass grafting\n* pregnancy or breastfeeding\n* history of blood malignancy or current solid-tumor malignancy\n* history of organ or stem cell transplantation\n* current treatment with prescription, systemic (oral, IV \\[intravenous\\], or IM \\[intramuscular\\]) steroids or anti-inflammatory\u002Fimmune suppressant medical therapies (including colchicine but excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDS) for autoimmune\u002Finflammatory diseases, post-transplant care, asthma, or pain\n* use of oral steroids or prescription oral anti-inflammatory\u002Fimmune suppressant medication for \\>7 days within the past 1 month\n* use of IV or IM steroids or IV or IM anti-inflammatory\u002Fimmune suppressant medication within the past 3 months\n* known allergy to dextran's and\u002For DTPA and\u002For radiometals and\u002For severe allergy to iodinated contrast media\n* estimated glomerular filtration rate (eGFR) \\\u003C 45 ml\u002Fmin\u002F1.73 m2\n* contraindications to nitroglycerin known narrow angle glaucoma, or known severe aortic stenosis\n* use of phosphodiesterase type 5 inhibitor AND refusal to abstain from use of these medications within the 5 days prior to scheduled CCTA scan\n* significant radiation exposure (40msV) received within the past 12 months\n* concurrent enrollment in another research study judged by the investigators to interfere with the current study\n* known active or recurrent hepatic disease (including cirrhosis or ALT\u002FAST levels \\>3 times the upper limit oof or total bilirubin \\>2 times the upper limits of normal)\n* history or evidence of tuberculosis (TB) (active or latent) infection or risk factor for TB\n* active bacterial, fungal or viral infection at the time of enrollment or history of recurrent infections\n* suspected or proven immunocompromised state\n* live vaccinations within 3 months prior to randomization visit or live vaccinations planned during the trial","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including those with and without clonal hematopoiesis driven by mutations in TET2.",[26,27,28],"Vascular Inflammation","ASCVD","ASCVD Management",[30,31,32,26,27,33],"CHIP","TET2 CHIP","Clonal Hematopoiesis","ASCVD management","RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":38},"2026-03-24",{"date":42,"type":20},"2030-04-01",{"name":44,"class":45},"Massachusetts General Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100616297","phase-2-efficacy-safety-and-poppk-profile-of-abp-745-in-patients-with-atherosclerosis-100616297","NCT07303777","Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics (PopPK) Profile of ABP-745 in Patients With Atherosclerosis","Inclusion Criteria:\n\nUnless otherwise specified, subjects must meet all of the following criteria at screening:\n\n* Diagnosed with coronary at herosclerosis, and coronary angiography.\n* Male or female at 18-75 years of age (inclusive).\n* Weight ≥40 kg.\n* Currently using any oral lipid-lowering therapy.\n* Able to understand and willing to sign an ICF and comply with study requirements.\n* A woman or man of childbearing potential agreeing to use medically approved contraceptive methods from the screening until 3 months after the last study dose.\n\nExclusion Criteria:\n\nUnless otherwise specified, subjects are excluded from the study if any of the following criteria is met:\n\n* History of stroke within the past 6 months.\n* Uncontrolled arrhythmia within 3 months prior to screening.\n* Evidence of any active or suspected cancer within 3 years prior to the screening.\n* Having undergone any major surgery within 3 months prior to the screening or planning to undergo any major surgery during the study.\n* Presence or suspicion of ongoing of any serious infection.\n* Human immunodeficiency virus (HIV) infection.","75 Years",{"count":56,"type":20},200,[23],"This is a multicenter, randomized, double-blind, placebo parallel controlled study to evaluate the preliminary efficacy, safety, and PopPK profile of ABP-745 in patients with ASCVD. Efficacy of ABP-745 in reducing atherosclerotic plaque compared with placebo will be evaluated in participants with ASCVD. The primary efficacy measurement will be assessed at 52W of treatment.",[60,27,28],"Atherosclerosis Cardiovascular Disease",[27,62],"ABP-745","2026-04-23",{"date":65,"type":38},"2026-04-28",{"date":63,"type":38},{"date":68,"type":20},"2028-04",{"name":70,"class":71},"Atom Therapeutics Co., Ltd","INDUSTRY",33,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":46},"100628663","optimizing-non-statin-agents-for-ascvd-100628663","NCT07464574","Optimizing Non-statin Agents for ASCVD","Using Pharmacy Extenders to Optimize Non-statin Agents for Secondary ASCVD Prevention Outcomes in a Federally Qualified Health Center","Inclusion Criteria:\n\n* Adult patients (\\>18 years) who have seen a CommUnityCare provider in the previous 12 months at time of enrollment, who have a documented history of clinical ASCVD, and are not achieving LDL targets (either \\\u003C55 or \\\u003C70 mg\u002FdL based on risk factors)\n\nExclusion Criteria:\n\n* Patients will be excluded if they do not have a clearly documented history clinical ASCVD, are already achieving LDL targets (either \\\u003C55 or \\\u003C70 mg\u002FdL based on risk factors), having cholesterol managed by outside provider (e.g. outside cardiologist\u002Flipid specialist), current pregnancy, have not seen a CUC provider in the previous 12 months, or otherwise do not qualify for clinical pharmacy intervention",{"count":81,"type":20},1000,"6 Months","OBSERVATIONAL","* The purpose of the study is to improve care for patients with high cholesterol.\n* If you choose to join the study, you will be asked to answer a phone call from study personnel. They will help you coordinate follow up appointments, review your medications and lab with you, and answer any questions you have about your medications. You will also continue to be seen by a clinical pharmacy team member. Your cholesterol medications may change to better lower your cholesterol. We will collect information about your visits, medicines, and cholesterol levels for 6 months.\n* If you choose not to participate, you will receive the same information and treatment at your next scheduled visit. You will receive the same care regardless of choosing to participate in the study.\n* Participation might involve a very low risk of some loss of privacy. There is low risk that someone outside the research study could see information about you.\n* A possible benefit is lower cholesterol.\n* Taking part in this research study is your choice. You do not have to participate, and you can stop at any time without any penalty.",[28],[87],"non-statin","2026-03-05",{"date":90,"type":38},"2026-03-11",{"date":92,"type":38},"2026-01-16",{"date":94,"type":20},"2027-05-01",{"name":96,"class":45},"University of Texas at Austin",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100617737","hearts-in-sync--cardiowatch-287-2-100617737","NCT07322510","HEARTS in Sync + CardioWatch 287-2","Health Behaviour Change, Education on Risk Factor Reduction, Physical Activity Guidance, and Nutrition Counselling With a Remote Team to Support Patient Progress Using Technology in Synchronization With Medication Management and CardioWatch 287-2. (HEARTS in Sync + CardioWatch 287-2)","Inclusion Criteria:\n\n* Patients who meet CR inclusion criteria requirements and who are enrolling in virtual cardiac rehab program, HEARTS in Sync, in Nova Scotia.\n\nExclusion Criteria:\n\nPhones that are not compatible with the Corsano system.\n\n* Huawei P8 Lite\n* Huawei P9 Lite\n* Xiaomi Mi 6\n* Huawei P20 Lite\n* Apple iOS version lower than 14.5\n* Android OS version lower than 8.0\n* Android or Apple devices without Bluetooth® 5.0 Low Energy capability",{"count":105,"type":20},216,[107],"NA","The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program.\n\nThe wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program.\n\nThe primary objectives of this study are to:\n\n1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not.\n2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by:\n\n   1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates,\n   2. Evaluating change in patient bloodwork outcomes,\n   3. Measuring change is physical ability,\n   4. Analyzing changes in eating behaviours, and\n   5. Examining quality of life using validated tools.\n3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by:\n\n   1. Assessing device adherence\n   2. Reviewing patient feedback survey, and\n   3. Determining if clinician team were able to access and interpret data collected throughout the program\n\nThe secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program.\n\nThis research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.",[110,111,28,112],"Wearable Device","Cardiovascular Disease","CHF - Congestive Heart Failure",[114,115,116],"virtual cardiac rehabilitation","wearable device","remote monitoring","NOT_YET_RECRUITING","2025-12-23",{"date":120,"type":38},"2026-01-07",{"date":122,"type":20},"2026-02",{"date":124,"type":20},"2029-02",{"name":126,"class":45},"Nova Scotia Health Authority"]